Equities researchers at Ascendiant Capital Markets assumed coverage on shares of IsoRay (NYSEAMERICAN:ISR) in a research report issued to clients and investors on Monday. The brokerage set a “buy” rating and a $1.00 price target on the healthcare company’s stock. Ascendiant Capital Markets’ target price points to a potential upside of 138.10% from the company’s current price.
Separately, Maxim Group set a $2.00 target price on IsoRay and gave the stock a “buy” rating in a report on Thursday, February 8th.
NYSEAMERICAN:ISR traded down $0.01 during mid-day trading on Monday, reaching $0.42. 76,400 shares of the company’s stock traded hands, compared to its average volume of 132,769. IsoRay has a 12-month low of $0.38 and a 12-month high of $0.64.
IsoRay Company Profile
IsoRay, Inc is a medical technology company. The Company, through its subsidiary, IsoRay Medical, Inc, develops, manufactures and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases. The Company is engaged in the production and sales of Cesium-131 (Cs-131) brachytherapy seeds.
Receive News & Ratings for IsoRay Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IsoRay and related companies with MarketBeat.com's FREE daily email newsletter.